News | EP Lab | September 27, 2017

Spectranetics Initiates Class I Recall for Bridge Occlusion Balloon Catheter

Company cites risk of blocked guidewire lumen preventing balloon utilization

Spectranetics Initiates Class I Recall for Bridge Occlusion Balloon Catheter

September 27, 2017 — Spectranetics is recalling its Bridge Occlusion Balloon Catheter due to the possibility of a blocked guidewire lumen in some device units. If a device with a blocked guidewire lumen were to be used during the procedure, the device would not be positioned correctly and hemorrhage would not be controlled. This would delay life-saving treatment, which may result in immediate and serious adverse health consequences, including death.

Devices in the following lot numbers are being recalled: FMN17B13A, FMN17C08A, FMN17C28A, FMN17D07A, FMN17D12A, FMN17D19A, FMN17D27A, FMN17E02A, FMN17E23A, FMN17E31A, FMN17E31B, FMN17F06A, FMN17F20A, FMN17F21A, FMN17G12A, FMN17G18A, FMN17H03A, FMN17H03A, FMN17H03A, FMN17H10A, FMN17H29A

The recall affects devices manufactured between Feb. 13 and July 18, 2017, and distributed between Feb. 24 and July 31 of this year. More than 1,900 devices are being recalled in total.

Spectranetics’ Bridge Occlusion Balloon Catheter is a device intended to temporarily block the superior vena cava (SVC) when emergency control of hemorrhage is required during lead extraction from an implantable device. The Bridge Occlusion Balloon catheter is constructed of a compliant balloon mounted on a dual lumen shaft. The guidewire lumen is used to pass the catheter over a guide wire.

On Aug. 7, 2017, Spectranetics sent affected customers an “Urgent Medical Device Recall” notice informing them of the device’s risks. The notice directed physicians to confirm that the guidewire lumen is open and unblocked prior to start of the procedure, and to have backup units on hand should they be needed during the procedure.

Spectranetics also sent affected customers an updated notice on Aug. 21, 2017 to notify them that all bridge devices have the potential for guidewire blockage. The updated notice recommended that physicians:

  • Place a guide wire through the venous access site and across the length of the SVC prior to the start of the procedure;
  • Consider removing the Bridge device from its packaging and placing the catheter over the guidewire prior to the start of the procedure to ensure a patent lumen.
    • If the guidewire lumen is obstructed, discard that device and test another until a working device has been identified. Return defective devices to Spectranetics;
  • Be aware that all Bridge inventory will continue to have the potential for a guidewire lumen blockage until Spectranetics has implemented a permanent solution;
  • Bring extra Bridge inventory into the procedure so that there is a back-up device on hand, should it be determined that the existing unit has a blocked guidewire lumen;
  • Always follow appropriate complication prevention and management protocols as they relate to patient preparation and surgical backup for lead extraction procedures; and
  • Complete and return to Spectranetics the “Acknowledgement and Receipt Form” that accompanied the Urgent Medical Device Recall notice.
  • A Spectranetics Sales Representative will be in contact to facilitate the return and replacement of any remaining inventory once new inventory with an implemented fix is available.

On Sept. 7, 2017, Spectranetics sent affected customers an additional notification informing them that follow-up distribution of the device is limited to a 30-day period.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program. They can either complete and submit the report online, download the form or call 1-800-332-1088 to request a reporting form.

Read the article "Study Shows Occlusion Balloon Saves Lives During Lead Extraction."

VIDEO: Demonstration of How the Bridge Occlusion Balloon Seals SVC Tears
 

For more information: www.spectranetics.com


Related Content

News | EP Lab

April 22, 2025 — Orchestra BioMed Holdings, a biomedical company accelerating high-impact technologies to patients ...

Home April 29, 2025
Home
News | EP Lab

April 21, 2025 — Stereotaxis, a provider of surgical robotics for minimally invasive endovascular intervention, will ...

Home April 21, 2025
Home
News | EP Lab

Feb. 12, 2025 — Orchestra BioMed Holdings, a biomedical company accelerating high-impact technologies to patients ...

Home February 14, 2025
Home
News | EP Lab

July 31, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home July 31, 2024
Home
News | EP Lab

July 17, 2024 — BioCardia, Inc., a company focused on cellular and cell-derived therapeutics for the treatment of ...

Home July 17, 2024
Home
News | EP Lab

June 25, 2024 — Heart Hospital of New Mexico at Lovelace Medical Center (HHNM) and GE HealthCare (announced HHNM as the ...

Home June 25, 2024
Home
News | EP Lab

May 30, 2024 — Stereotaxis, a pioneer in surgical robotics for minimally invasive endovascular intervention, announced ...

Home May 30, 2024
Home
News | EP Lab

May 21, 2024 — Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular ...

Home May 21, 2024
Home
News | EP Lab

February 2, 2024 — GE HealthCare (Nasdaq: GEHC) announces the latest innovation in electrophysiology (EP), the Prucka 3 ...

Home February 02, 2024
Home
News | EP Lab

January 11, 2024 — It is with great sadness that the Diagnostic and Interventional Cardiology (DAIC) team has learned of ...

Home January 11, 2024
Home
Subscribe Now